Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Related News
Insights
Company Spotlight
Stealth Biotherapeutics is an American biotech with a focus on mitochondrial therapies, in fields as diverse as metabolics, neurology and musculoskeletal.
Latest News & Features of interest to Merck KGaA
Biotechnology
Norway-based clinical-stage immunologics company Calluna Pharma today announced the appointment of Margrethe Sørgaard to the position of senior vice president of clinical operations and pharmacovigilance. 24 April 2024
Biotechnology
Biogen presented its first-quarter 2024 financial results on Wednesday. 24 April 2024
Biotechnology
Day One Biopharmaceuticals closed Tuesday’s trading 8% higher on positive regulatory news. 24 April 2024
Pharmaceutical
A Takeda Pharmaceutical-partnered program has delivered strong mid-stage data, sending shares in Neurocrine Biosciences up 5%. 24 April 2024
Biotechnology
The US Food and Drug Administration has approved Lutathera (lutetium Lu 177 dotatate, from Advanced Accelerator Applications USA, a Novartis company). 24 April 2024
Pharmaceutical
A single-line order from the US Supreme Court has scotched hopes on the part of Vanda Pharmaceuticals of resurrecting patents for Hetlioz (tasimelteon). 23 April 2024
Biotechnology
In a bid to expand its portfolio of immunology products, US biotech Incyte today announced it plans to acquire privately-held Escient Pharmaceuticals. 23 April 2024
Biotechnology
Long-term partners BioArctic and Eisai have announced a new research agreement regarding BAN2802, a potential treatment combining the former company’s proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate. 23 April 2024
Pharmaceutical
San Diegan cancer company Kura Oncology has picked up Breakthrough Therapy designation for its menin inhibitor ziftomenib. 23 April 2024
Biotechnology
French drugmaker Ipsen says it has signed an exclusive worldwide collaboration with privately-held US biotech Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases. 23 April 2024
Latest In Brief for Merck KGaA
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Latest Relevant Ones To Watch News
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
8 October 2024
8 October 2024
24 September 2024
9 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze